Antiretroviral drug of Cipla receives approval from South African regulator

Cipla’s first-line triple-combination treatment for HIV receives approval from the South African Health Products Regulatory Authority (SAHPRA). The newly developed combination drug will be produced locally for the African market.

The triple-combination antiretroviral (ARV) will be used as a first-line of treatment for HIV patients. The ARV combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG) is called TLD. The drug will be manufactured at Cipla’s Durban and Uganda facilities. The manufacturing of this drug involves complex processes which will require investment in technology and infrastructure of approximately 48 million South African Rand. However, the medication is significantly affordable to patients.

Meanwhile, on Wednesday, the stock of Cipla Limited was trading in-line with the benchmark index. The stock opened at Rs. 654.90 per share and hit a high of Rs. 662.00 per share on BSE. At 10:52 hours, the stock was at Rs. 657.00 per share, up by 0.24 per cent, when the benchmark index was at 37,500.86, up by 87.73 points or 0.23 per cent.